PUBLISHER: DelveInsight | PRODUCT CODE: 1226531
PUBLISHER: DelveInsight | PRODUCT CODE: 1226531
"ADCETRIS Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ADCETRIS for Cutaneous T-cell lymphoma (CTCL) in the seven major markets. A detailed picture of the ADCETRIS for Cutaneous T-cell lymphoma in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the ADCETRIS for Cutaneous T-cell lymphoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ADCETRIS market forecast, analysis for Cutaneous T-cell lymphoma in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Cutaneous T-cell lymphoma.
ADCETRIS (Brentuximab vedotin) targets CD30 using our proprietary antibody-drug conjugate (ADC) technology. CD30 is found on the surface of most classical Hodgkin lymphoma (HL) cells and in several types of non-Hodgkin lymphoma but is not commonly found on healthy cells. This ADC therapy uses a linker system that is designed to be stable in the bloodstream and release a cytotoxic (cell-killing) agent once internalized into CD30-expressing cells, resulting in targeted cell death. Brentuximab vedotin is composed of an anti-CD30 monoclonal antibody and a cytotoxic agent, monomethyl auristatin E (MMAE), which are attached by a protease-cleavable linker.
The prescribing information for ADCETRIS also includes a boxed warning related to the risk that JC virus infection resulting in progressive multifocal leukoencephalopathy and death can occur in patients receiving ADCETRIS. The drug is being developed in collaboration with Takeda Pharmaceutical Company. Beyond the current labeled indications, the company is evaluating ADCETRIS as monotherapy and in combination with other agents in ongoing trials.
ADCETRIS injection for intravenous infusion has received FDA approval for four indications, including regular approval for patients with pcALCL and CD30-expressing MF and who have received prior systemic therapy. CD30 is a member of the tumor necrosis factor receptor family. It is expressed on the surface of sALCL cells and on Hodgkin Reed-Sternberg (HRS) cells in cHL and has limited expression on healthy tissue and cells. In vitro data suggest that signaling through CD30-CD30L binding may affect cell survival and proliferation. Brentuximab vedotin is an ADC. The antibody is a chimeric IgG1 directed against CD30. The small molecule, MMAE, is a microtubule-disrupting agent, and MMAE is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of ADCETRIS is due to the binding of the ADC to CD30-expressing cells, followed by internalization of the ADC-CD30 complex and the release of MMAE via proteolytic cleavage. The binding of MMAE to tubulin disrupts the microtubule network within the cell, causing cell cycle arrest and apoptotic death of the cells. Additionally, in vitro data prove antibody-dependent cellular phagocytosis (ADCP).
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ADCETRIS Analytical Perspective by DelveInsight
This report provides a detailed market assessment of ADCETRIS in Cutaneous T-cell lymphoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of ADCETRIS in Cutaneous T-cell lymphoma covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions